These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36431337)

  • 21. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
    Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
    Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
    Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism.
    Mitsopoulos E; Zanos S; Ginikopoulou E; Kyriklidou P; Meimaridou D; Sakellariou G
    Am J Kidney Dis; 2006 Jul; 48(1):114-21. PubMed ID: 16797393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of microwave ablation for ectopic secondary hyperparathyroidism: a feasibility study.
    Li X; Wei Y; Shao H; Peng L; An C; Yu MA
    Int J Hyperthermia; 2019; 36(1):647-653. PubMed ID: 31305184
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients.
    Zawierucha J; Małyszko J; Małyszko JS; Prystacki T; Marcinkowski W; Dryl-Rydzyńska T
    Pol Arch Intern Med; 2017 Dec; 127(12):840-845. PubMed ID: 29067991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of calcitriol on secondary hyperparathyroidism].
    Xu H; Zhang J; Cheng X; Zhou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.
    Coyne DW; Andress DL; Amdahl MJ; Ritz E; de Zeeuw D
    Nephrol Dial Transplant; 2013 Sep; 28(9):2260-8. PubMed ID: 23787544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease.
    Webb NJA; Lerner G; Warady BA; Dell KM; Greenbaum LA; Ariceta G; Hoppe B; Linde P; Lee HJ; Eldred A; Dufek MB
    Pediatr Nephrol; 2017 Jul; 32(7):1221-1232. PubMed ID: 28332096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
    Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
    Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
    J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study.
    Hadjiyannakos D; Filiopoulos V; Trompouki S; Sonikian M; Karatzas I; Panagiotopoulos K; Vlassopoulos D
    Clin Kidney J; 2013 Apr; 6(2):164-8. PubMed ID: 26019845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients.
    Zheng JQ; Hou YC; Zheng CM; Lu CL; Liu WC; Wu CC; Huang MT; Lin YF; Lu KC
    Nutrients; 2016 Nov; 8(11):. PubMed ID: 27827962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and initial dose determination of paricalcitol for treatment of secondary hyperparathyroidism in Chinese subjects.
    Yan Y; Qian J; Chen N; Huang Z; Jiang G; Li X; Lin H; Liu L; Wang M; Xing C; Yu X; Zuo L; Amdahl M; Khan S
    Clin Nephrol; 2014 Jan; 81(1):20-9. PubMed ID: 24131674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials.
    Xie Y; Su P; Sun Y; Zhang H; Zhao R; Li L; Meng L
    BMC Nephrol; 2017 Aug; 18(1):272. PubMed ID: 28841848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Therapy Outcomes When Treating Chronic Kidney Disease Patients with Paricalcitol in German and Austrian Clinical Practice (TOP Study).
    Obermüller N; Rosenkranz AR; Müller HW; Hidde D; Veres A; Decker-Burgard S; Weisz I; Geiger H
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28956807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
    Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
    Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
    de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
    Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.